Organization · Venture Capital
BioAdvance Capital
BioAdvance Capital is an evergreen fund based in Conshohocken, Pennsylvania, that invests in early-stage life-science companies focused on improving human health. The firm primarily targets investments along the I-95 corridor in the Mid-Atlantic region.
Overview
What BioAdvance Capital does
What BioAdvance Capital is
BioAdvance Capital is an evergreen fund based in Conshohocken, Pennsylvania, that invests in early-stage life-science companies focused on improving human health. The firm primarily targets investments along the I-95 corridor in the Mid-Atlantic region.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find BioAdvance Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
BioAdvance Capital as a funder
Investment thesis
BioAdvance Capital focuses on backing early-stage human-health technologies in the Mid-Atlantic region that can achieve significant milestones, making them attractive to later-stage investors and strategic partners.
Focus narrative
BioAdvance Capital invests in early-stage life-science companies, particularly in therapeutics, medical devices, digital health, diagnostics, and research tools. The organization primarily targets seed and Series A investment opportunities, providing funding that enables companies to reach critical milestones that enhance their appeal to larger venture capital firms and other funding sources.
Value beyond capital
BioAdvance Capital adds value to its portfolio companies through hands-on support and sector expertise, helping them achieve critical milestones that attract further investment and strategic partnerships.
Terms and economics
- Typical check
- $500,000–$1,500,000
- Sweet spot
- $1,000,000
Focus and fit
- Stages
- Seed · Series A
- Sectors
- Biotech · Healthcare · Digital Health · Medical Devices · Diagnostics
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 120
Portfolio context
BioAdvance Capital has invested in over 120 companies, including notable portfolio companies such as Accelerated Biosciences, Acuity Pharmaceuticals, Allevi, Annovis, Avid Radiopharmaceuticals, ImmunoGenesis, Oncora Medical, Relmada Therapeutics, and Venatorx Pharmaceuticals. These companies have collectively attracted over $4.4 billion in follow-on funding.
Common questions
What to know about BioAdvance Capital
Upseed classifies BioAdvance Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.